Specific T cell responses to Helicobacter pylori predict successful eradication therapy

Journal of Infection

Volumn 54, Issue 3, 2007, Pages 257-261

  Kopitar, A N ^a   Stegel, V ^b   Tepes B ^c   Gubina, M ^a   Novakovic S ^b   Ihan, A ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c Health Centre Rogaska   (Slovenia)

Author keywords

Cytokines; Dendritic cells; Helicobacter pylori; Therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; CD69 ANTIGEN; CLARITHROMYCIN; CYTOKINE; GAMMA INTERFERON; HELICOBACTER PYLORI VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; METRONIDAZOLE; MONOCLONAL ANTIBODY; PROTON PUMP INHIBITOR; TINIDAZOLE;

AGED; ARTICLE; BACTERIUM CULTURE; BLOOD SAMPLING; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DYSPEPSIA; ERADICATION THERAPY; FLOW CYTOMETRY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MONONUCLEAR CELL; PREDICTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, BACTERIAL; CELLS, CULTURED; DENDRITIC CELLS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOASSAY; INTERFERON TYPE II; INTERLEUKIN-4; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33846958727     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.05.009     Document Type: Article

References (18)

1. Marshall B.J., and Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 8390 (Jun 16, 1984) 1311-1315
2. Velduyzen van Zanten S.J.O., and Sherman P.M. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 150 (1994) 177-185
3. Asghar R.J., and Parsonnet J. Helicobacter pylori and risk for gastric adenocarcinoma. Semin Gastrointest Dis 12 (2001) 203-208
4. Bell G.D., Powell K.U., Burridge S.M., Bowden A.F., Atoyebi W., Bolton G.H., et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 9 (1995) 41-46
5. Lind T., Megraud F., Unge P., Bayerdorffer E., O'Morain C., Spiller R., et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116 (1999) 248-253
6. Malfertheiner P., Megraud F., O'Morain C., Hungin A.P.S., Jones R., Axon A., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 16 (2002) 167-180
7. Hirschl A.M., and Rotter M.L. Amoxicillin for the treatment of Helicobacter pylori infection. J Gastroenterol 31 Suppl. 9 (1996) 44-47
8. Goddard A.F., Jessa M.J., Barrett D.A., Shaw P.N., Idstrom J.P., Cederberg C., et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111 (1996) 358-367
9. Kuipers E.J., Kusters J.G., and Deboer W.A. Current therapies of Helicobacter pylori infection. Bailliere's Clin Infect Dis 4 (1997) 395-412
10. Sander J.O., van Zanten V., Kolesnikow T., Leung V., O'Rourke J.L., and Lee A. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrobial Agents and Chemotherapy 47 (2003) 2249-2255
11. Luzza F., Parrello T., Sebkova L., Pensabene L., Imeneo M., Mancuso M., et al. Expression of proinflammatory and Th1 but not Th2 cytokines is enhanced in gastric mucosa of Helicobacter pylori infected children. Digest Liver Dis 33 (2001) 14-20
12. Miyashita M., Joh T., Watanabe K., Todoraki I., Seno K., Ohara O., et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine 20 (2002) 2336-2342
13. Jiang W., Baker H.J., and Smith B.F. Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun 71 (2003) 40-46
14. Borody T., Ren Z., Pang G., and Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol 97 (2002) 3032-3037
15. Tepeš B., Kavčič B., Zaletel-Kragelj L., Gubina M., Ihan A., Poljak M., et al. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 188 (1999) 24-29
16. Ihan A., Tepeš B., Gubina M., Malovrh T., and Kopitar A. Diminished interferon gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Hepatogastroenterology 46 (1999) 1740-1745
17. Ihan A., Tepeš B., and Gubina M. Diminished Th1-type cytokine production in gastric mucosa T-lymphocytes after H. pylori eradication in duodenal ulcer patients. Pflugers Arch 440 Suppl. 5 (2000) R89-R90
18. Tsuneyasu K., and Shizuo A. Toll-like receptors as adjuvant receptors. Biochem Biophys Acta 1589 (2002) 1-13